Ibotenic acid and thioibotenic acid: a remarkable difference in activity at group III metabotropic glutamate receptors

Mette B Hermit, Jeremy R Greenwood, Birgitte Nielsen, Lennart Bunch, Charlotte G Jørgensen, Henrik T Vestergaard, Tine B Stensbøl, Connie Sanchez, Povl Krogsgaard-Larsen, Ulf Madsen, Hans Bräuner-Osborne

    45 Citations (Scopus)

    Abstract

    In this study, we have determined and compared the pharmacological profiles of ibotenic acid and its isothiazole analogue thioibotenic acid at native rat ionotropic glutamate (iGlu) receptors and at recombinant rat metabotropic glutamate (mGlu) receptors expressed in mammalian cell lines. Thioibotenic acid has a distinct pharmacological profile at group III mGlu receptors compared with the closely structurally related ibotenic acid; the former is a potent (low microm) agonist, whereas the latter is inactive. By comparing the conformational energy profiles of ibotenic and thioibotenic acid with the conformations preferred by the ligands upon docking to mGlu1 and models of the other mGlu subtypes, we propose that unlike other subtypes, group III mGlu receptor binding sites require a ligand conformation at an energy level which is prohibitively expensive for ibotenic acid, but not for thioibotenic acid. These studies demonstrate how subtle differences in chemical structures can result in profound differences in pharmacological activity.
    Original languageEnglish
    JournalEuropean Journal of Pharmacology
    Volume486
    Issue number3
    Pages (from-to)241-50
    ISSN0014-2999
    DOIs
    Publication statusPublished - 23 Feb 2004

    Keywords

    • Animals
    • CHO Cells
    • Cricetinae
    • Cricetulus
    • Excitatory Amino Acid Agonists
    • Ibotenic Acid
    • Ligands
    • Male
    • Mice
    • Models, Molecular
    • Molecular Conformation
    • Radioligand Assay
    • Rats
    • Receptors, Metabotropic Glutamate
    • Thiazoles

    Fingerprint

    Dive into the research topics of 'Ibotenic acid and thioibotenic acid: a remarkable difference in activity at group III metabotropic glutamate receptors'. Together they form a unique fingerprint.

    Cite this